# Tremfya

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/tremfya
Canonical HTML page: https://gethealthbrief.com/entity/tremfya

## Recent coverage (1 stories)

### J&J’s $100B Revenue Runway: How Next-Gen Drugs Are Plugging the Stelara Gap
2026-07-20 00:11:51 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

J&J’s Q2 2026 earnings beat underscores a successful pivot away from Stelara’s $10B peak. New oncology and immunology drugs are powering growth, with full-year revenue now expected to top $100B. For healthcare stakeholders, this signals pipeline resilience and a defensive stock offering amid sector headwinds.
Full story: https://gethealthbrief.com/story/jnj-100b-pharma-pipeline-stelara-gap-health

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.